References
- G. Walsh and E. Walsh, Biopharmaceutical benchmarks 2022, Nat. Biotechnol. 40 (2022) 1722–1760; https://doi.org/10.1038/s41587-022-01582-x
- N. C. Pace and C. Tanford, Thermodynamics of the unfolding of β-lactoglobulin A in aqueous urea solutions between 5 and 55°, Biochemistry 7 (1968) 198–208; https://doi.org/10.1021/bi00841a025
- F. Jameel and S. Hershenson, Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals, John Wiley & Sons, New Jersey 2002, pp. 69–105.
- L. O. Narhi, J. Schmit, K. Bechtold-Peters and D. Sharma, Classification of protein aggregates, J. Pharm. Sci. 101 (2012) 493–498; https://doi.org/10.1002/jps.22790
- S. Hermeling, D. J. A. Crommelin, H. Schellekens and W. Jiskoot, Structure-immunogenicity relationships of therapeutic proteins, Pharm. Res. 21 (2004) 897–903; https://doi.org/10.1023/B:PHAM.0000029275.41323.a6
- A. Braun, L. Kwee, M. A. Labow and J. Alsenz, Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-α) in normal and transgenic mice, Pharm. Res. (1997) 1472–1478; https://doi.org/10.1023/A:1012193326789
- Y. Le Basle, P. Chennell, N. Tokhadze, A. Astier and V. Sautou, Physicochemical stability of monoclonal antibodies: A review, J. Pharm. Sci. 109 (2020) 169–190; https://doi.org/10.1016/j.xphs.2019.08.009
- E. Y. Chi, S. Krishnan, T. W. Randolph and J. F. Carpenter, Physical stability of proteins in aqueous solution: Mechanism and driving forces in nonnative protein aggregation, Pharm. Res. 20 (2003) 1325–1336; https://doi.org/10.1023/A:1025771421906
- E. Y. Chi, Excipients and their effects on the quality of biologics, Aaps 1 (2012) 1–12.
- E. Proksch, Buffering capacity, Curr. Probl. Dermatology 54 (2018) 11–18; https://doi.org/10.1159/000489513
- E. T. Urbansky and M. R. Schock, Understanding, deriving, and computing buffer capacity, J. Chem. Educ. 77 (2000) 1640–1644; https://doi.org/10.1021/ed077p1640
- B. N. Dominy, D. Perl, F. X. Schmid and C. L. Brooks, The effects of ionic strength on protein stability: The cold shock protein family, J. Mol. Biol. 319 (2002) 541–554; https://doi.org/10.1016/S0022-2836(02)00259-0
- S. O. Ugwu and A. P. Shireesh, The effect of buffers on protein conformational stability, Pharm. Technol. 81 (2004) 339–352; https://doi.org/10.1016/j.saa.2011.06.021
- T. J. Zbacnik, R. E. Holcomb, D. S. Katayama, B. M. Murphy, R. W. Payne, R. C. Coccaro, G. J. Evans, J. E. Matsuura, C. S. Henry and M. C. Manning, Role of buffers in protein formulations, J. Pharm. Sci. 106 (2017) 713–733; https://doi.org/10.1016/j.xphs.2016.11.014
- R. N. Goldberg, N. Kishore and R. M. Lennen, Thermodynamic quantities for the ionization reactions of buffers, J. Phys. Chem. Ref. Data 31 (2002) 231–370; https://doi.org/10.1063/1.1416902
- K. C. Waterman, R. C. Adami, K. M. Alsante, J. Hong, M. S. Landis, F. Lombardo and C. J. Roberts, Stabilization of pharmaceuticals to oxidative degradation, Pharm. Dev. Technol. 7 (2002) 1–32; https://doi.org/10.1081/PDT-120002237
- Y. H. Kim and W. E. Stites, Excluded volume effects upon protein stability in covalently crosslinked proteins with variable linker lengths, Bone 23 (2011) 1–7; https://doi.org/10.1021/bi800297j
- C. Du, G. Barnett, A. Borwankar, A. Lewandowski, N. Singh, S. Ghose, M. Borys and Z. J. Li, Protection of therapeutic antibodies from visible light induced degradation: Use safe light in manufacturing and storage, Eur. J. Pharm. Biopharm. 127 (2018) 37–43; https://doi.org/10.1016/j.ejpb.2018.02.007
- M. Lei, C. Quan, Y. J. Wang, Y. H. Kao and C. Schöneich, Light-induced covalent buffer adducts to histidine in a model protein, Pharm. Res. 35 (2018); https://doi.org/10.1007/s11095-017-2339-4
- S. D. Stroop, D. M. Conca, R. P. Lundgard, M. E. Renz, L. M. Peabody and S. D. Leigh, Photosensitizers form in histidine buffer and mediate the photodegradation of a monoclonal antibody, J. Pharm. Sci. 100 (2011) 5142–5155; https://doi.org/10.1002/jps.22714